CancerDrs

Multiple Myeloma clinical trials in Mississippi

5 actively recruiting multiple myeloma trials at 4 sites across Mississippi.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full multiple myeloma transparency page →

Phase 3 Recruiting Network

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Mississippi:
  • Gulfport Memorial Hospital — Gulfport, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…

Sponsor: Celgene
NCT ID: NCT05519085
Sites in Mississippi:
  • Local Institution - 0088 — Hattiesburg, Mississippi
  • Local Institution - 0242 — Jackson, Mississippi
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Mississippi:
  • Hattiesburg Clinic - Hematology & Oncology — Hattiesburg, Mississippi
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in Mississippi:
  • Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Mississippi:
  • Univeristy of Mississippi Medical Center — Jackson, Mississippi
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25